Table 1 Baseline characteristics of the HER2-positive metastatic breast cancer patients included in the study.
Characteristic | N = 70 |
|---|---|
N (%) | |
Age,years | |
Median (range, years) | 47 (29–68) |
Menopausal status | |
Pre-menopausal | 31 (46.3) |
Post-menopausal | 34 (48.6) |
Gender | |
Female | 68 (97.1) |
Male | 2 (2.9) |
ECOG performance status | |
0 | 5 (7.1) |
1 | 60 (85.7) |
2 | 5 (7.1) |
Hormone receptor status | |
ER + and/or PR + | 45 (64.3) |
ER − and PR − | 25 (35.7) |
Visceral disease involvement | |
Yes | 46 (65.7) |
No | 24 (34.3) |
Number of metastatic sites | |
3 or less | 31 (44.3) |
> 3 | 39 (55.7) |
CNS metastases | |
Yes | 28 (40) |
No | 42 (60) |
Previous treatment | |
Number of treatment lines – Median (range) | 2.5 (1–7) |
Hormonal therapy | 40 (25.7%) |
Trastuzumab | 70 (100%) |
Capecitabine-lapatinib | 49 (70%) |
Anthracyclines | 28 (40%) |
Taxanes | 55 (78.6%) |
Gemcitabine | 13 (18.5%) |
Vinorelbine | 2 (2.8%) |
T-DM1 treatment line | |
Second | 18 (25.7) |
Third | 38 (54.3) |
Fourth | 10 (14.2) |
Fifth | 1 (1.4) |
Sixth or more | 3 (4.3) |
Number of T-DM1 cycles of T-DM1 cycles Median (range) | 6 (1–38) |
